Genomic Health

Genomic Health
Name	Genomic Health
Type	Public (acquired)
Industry	Biotechnology
Founded	2000
Fate	Acquired by Exact Sciences (2019)
Headquarters	Redwood City, California, United States
Key people	Randy Scott, Kim Popovits
Products	Oncotype DX
Revenue	(historical)

Genomic Health Genomic Health was a biotechnology company specializing in genomic assays for oncology, notable for commercializing the Oncotype DX breast cancer assay and advancing molecular diagnostics. The company developed standardized gene-expression tests intended to guide therapy decisions and prognostication, worked with academic institutions and hospitals, and was acquired by Exact Sciences in 2019.

Overview and Definitions

Genomic Health focused on molecular diagnostics, translational research, and commercial assay development, bridging biotechnology startups, clinical laboratories, and academic centers such as Johns Hopkins University, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute. Its flagship product, Oncotype DX, was developed with collaborators including researchers from Genentech and clinical trial groups like the NSABP and TAILORx trial investigators. The company operated in the regulatory landscape involving agencies and frameworks such as the Food and Drug Administration, Centers for Medicare & Medicaid Services, and reimbursement negotiations with insurers like UnitedHealthcare and Aetna.

Genetic Variation and Population Genomics

Work at the company intersected with concepts studied by consortia and projects like the 1000 Genomes Project, the Human Genome Project, and initiatives involving population genetics at institutions such as Wellcome Trust Sanger Institute, Broad Institute, and European Bioinformatics Institute. Panels and assays relied on catalogues of somatic and germline variation curated by resources including ClinVar, COSMIC, and datasets generated by collaborations with academic cancer centers and cooperative groups such as the American Society of Clinical Oncology. Population-specific allele frequencies and variant interpretation drew on studies from research groups at University of California, San Francisco, Stanford University, and international consortia like ICGC and TCGA.

Genomic Technologies and Testing Methods

Assays developed and commercialized used technologies and platforms related to quantitative reverse transcription PCR, next-generation sequencing platforms from firms such as Illumina, and laboratory workflows influenced by standards from organizations like College of American Pathologists and Clinical Laboratory Improvement Amendments. Test validation, analytic sensitivity, and reproducibility referenced methodologies pioneered at research laboratories affiliated with Cold Spring Harbor Laboratory, Salk Institute, and university cores at Harvard Medical School and Massachusetts Institute of Technology. Quality-control and proficiency testing connected to programs run by American College of Medical Genetics and Genomics and specimen handling guidelines from networks like National Cancer Institute cooperative groups.

Clinical Applications and Personalized Medicine

Oncotype DX and related genomic assays were applied in treatment decision-making for early-stage breast cancer, influencing adjuvant chemotherapy recommendations guided by clinical trials including TAILORx, MINDACT, and cooperative group studies from NSABP and EORTC. The company’s clinical evidence base intersected with practice guidelines from professional societies such as American Society of Clinical Oncology and NCCN. Applications extended to prostate cancer, colorectal cancer, and other tumor types through collaborations with academic centers including Vanderbilt University Medical Center, University of Texas MD Anderson Cancer Center, and University College London. Health technology assessment and cost-effectiveness evaluations involved agencies and institutions like Institute for Clinical and Economic Review, National Institute for Health and Care Excellence, and payer entities such as Centers for Medicare & Medicaid Services.

Public Health, Ethics, and Policy

Commercialization of genomic assays engaged regulatory, ethical, and policy debates involving the Food and Drug Administration, patent disputes related to genetic testing that involved precedents like Association for Molecular Pathology v. Myriad Genetics, and reimbursement policy discussions with federal programs and private insurers. Issues of equitable access and disparities invoked stakeholders including World Health Organization initiatives, public health programs at Centers for Disease Control and Prevention, and bioethics scholarship from institutions such as Georgetown University and Harvard School of Public Health. Data sharing, consent, and privacy concerns related to genomic data linked to standards and policies from Health Insurance Portability and Accountability Act discussions and best practices advocated by groups like Global Alliance for Genomics and Health.

Research, Data Analysis, and Bioinformatics

Development and validation of genomic signatures required bioinformatics pipelines and statistical methodologies developed in academic contexts at the Broad Institute, Stanford University School of Medicine, and University of California, Berkeley. Tools and resources integrated into analysis workflows included reference databases like RefSeq, variant annotation systems influenced by Ensembl, and computational methods described in publications from researchers affiliated with Cold Spring Harbor Laboratory, MIT, and Harvard University. Collaborative clinical trials and registries involved data coordination centers such as those at Fred Hutchinson Cancer Center and data governance frameworks aligned with initiatives from NIH and cooperative groups such as SWOG and Alliance for Clinical Trials in Oncology.

Category:Biotechnology companies